Clinical trial NCT05373199: A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
Official title: A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 1 Diabetes
Lead sponsor: Adocia
Sponsor class: INDUSTRY
Collaborators: name: Tonghua Dongbao Pharmaceutical Co.,Ltd
First posted: 2022-05-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Three-period crossover
Primary purpose: TREATMENT

Brief summary: This is a randomised, double-blind, three-period crossover euglycaemic clamp trial comparing pharmacokinetics and pharmacodynamics of BC Combo THDB0207 and Lantus® and Humalog® in subjects with type 1 diabetes.

Each subject will be randomly allocated to one of the 6 treatment sequences and will be administered single subcutaneous doses of BC Combo THDB0207, Lantus®, and Humalog® at three separate dosing visits.

Subjects will come in a fasted state to the clinical trial centre in the morning of each dosing day and stay at the clinical trial centre until the 24-hour clamp procedures have been terminated. Patients will return to the clinical trial centre for outpatient blood sampling visits for analysis of BC449 excipient until 144 hours after each dosing.

Detailed description: Subjects will attend the study site in the morning in a fasted state and will be connected to an automated glucose clamp device (ClampArt). Prior to dose administration plasma glucose will be stabilised at a target level of 100 mg/dL by means of an intravenous infusion of glucose or insulin. IMP administration will be done by an unblinded person by means of subcutaneous injections in the abdominal wall.

Following each dosing a euglycaemic glucose clamp procedure will be carried out for up to 24 hours.

The pharmacodynamic assessment will be based on the time course of glucose infusion rate (GIR) and plasma glucose.

Plasma insulin concentrations will be measured using a specific validated bioanalytical method differentiating concentrations of insulin glargine, of its main metabolites insulin glargine-M1 and insulin glargine-M2, and of insulin lispro. Pharmacokinetic assessments will be based on total insulin (INS) concentration (insulin glargine + insulin glargine-M1 + insulin glargine-M2 + insulin lispro).

The investigation of PK properties of the BC449 excipient after dosing with BC Combo THDB0207 will be based on blood samples collected during the clamp procedure and at daily outpatient visits until 144 hours after dose administration.

Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes mellitus (as diagnosed clinically) for ≥ 12 months
* HbA1c ≤8.5%
* Total insulin dose of \< 1.2 U/kg/day
* BMI between 20.0 and 29.9 kg/m2 (both inclusive)
* Treated with insulin regimen for ≥ 12 months prior to screening
* Using multiple dosing insulin therapy (MDI) with basal and bolus insulin or insulin pump therapy (continuous subcutaneous insulin infusion, CSII)
* Fasting C-peptide \<= 0.30 nmol/L

Exclusion Criteria:

* Known or suspected hypersensitivity to the IMPs or any of the excipients or to any component of the IMP formulation.
* Type 2 diabetes mellitus
* Use of oral antidiabetic drugs (OADs) and/or GLP-1 receptor agonists (e.g. exenatide, liraglutide)
* Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial
* Clinically significant abnormal screening laboratory tests, as judged by the Investigator considering the underlying disease
* Clinically relevant comorbidity, capable of constituting a risk for the subject when participating in the trial or of interfering with the interpretation of data
* Systolic blood pressure \< 90 mmHg or \>139 mmHg and/or diastolic blood pressure \< 50 mmHg or \> 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension)
* Heart rate at rest outside the range of 50-90 beats per minute.
* More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months or hypoglycaemia unawareness as judged by the investigator
* Women of childbearing potential who are not using a highly effective contraceptive method.

Primary outcomes:
measure: AUCGIR 0-6h
timeFrame: From t=0 to t=6 hours after IMP administration
measure: AUCGIR 6-24h
timeFrame: From t=6 to t=24 hours after IMP administration
Secondary outcomes:
measure: AUCGIR 0-last
timeFrame: From t=0 to t=24 hours after IMP administration
measure: AUCGIR 0-4h
timeFrame: From t=0 to t=4 hours after IMP administration
measure: GIRmax
timeFrame: From t=0 to t=24 hours
measure: tGIRmax
timeFrame: From t=0 to t=24 hours
measure: tonset of action
timeFrame: From t=0 to t=24 hours after IMP administration
measure: AUCINS 0-6h
timeFrame: From t=0 to t=6 hours after IMP administration
measure: AUCINS 0-24h
timeFrame: From t=0 to t=24 hours after IMP administration
measure: AUCINS 6-24h
timeFrame: From t=6 to t=24 hours after IMP administration
measure: AUCINS 4-12h
timeFrame: From t=4 to t=12 hours after IMP administration
measure: AUCINS 0-4h
timeFrame: From t=0 to t=4 hours after IMP administration
measure: AUCINSlast
timeFrame: From t=0 to t=24 hours
measure: Cmax INS
timeFrame: From t=0 to t=24 hours after IMP administration
measure: RBA
timeFrame: From t=0 to t=24 hours after IMP administration
measure: AUCBC 0-12h
timeFrame: From t=0 to t=12 hours after IMP administration
measure: AUCBC 0-24h
timeFrame: From t=0 to t=24 hours after IMP administration
measure: AUCBC 0-last
timeFrame: From t=0 to t=144 hours after IMP administration
measure: Adverse Events
timeFrame: From the first IMP administration to the follow-up visit (i.e. up to 11 weeks)
measure: Local tolerability
timeFrame: From the first IMP administration to the follow-up visit (i.e. up to 11 weeks)
Other outcomes:
Locations:
city: Neuss
country: Germany
facility: Profil Institut für Stoffwechselforschung GmbH
Study officials:
affiliation: Profil Institut für Stoffwechselforschung GmbH
name: Marc Stoffel, MD
role: PRINCIPAL_INVESTIGATOR
References: